Clear Street ups Delcath target, sees opportunity on selloff

Clear Street raised the firm’s price target on Delcath Systems (DCTH) to $28 from $27 and keeps a Buy rating on the shares. The stock is trading lower on the company’s “soft” preliminary Q3 results and 2025 revenue guidance, the analyst tells investors in a research note. However, the firm attributes the results to pricing dynamics and new patient starts, which it feels are “likely a blip.” The CHOPIN trial results will lead to increased penetration of Hpezato into the metastatic uveal melanoma population, contends Clear Street. The firm sees today’s selloff as a buying opportunity. The stock is down 5% to $11.38 in midday trading.